April 25, 2023 — FastWave Medical, a privately-held company founded by Big Sky Biomedical partners, announces the issuance of its second utility patent by the USPTO. This milestone showcases FastWave Medical's unparalleled efficiency in developing novel intravascular lithotripsy (IVL) systems to address the $9 billion market.
"Our second utility patent from the USPTO in just over a year highlights the rapid progress our team has made in advancing IVL treatments for cardiovascular calcium," said Scott Nelson, CEO and Co-Founder of FastWave Medical. "Our innovative technology platforms are designed to offer a more efficient, effective, and cost-conscious solution that addresses the current limitations with existing IVL interventions, propelling the industry forward at an unprecedented pace."
Artery calcification is a critical predictor of adverse cardiac events. With an aging global population and a substantial number of individuals over 70 affected by the disease, the need for effective treatment options has never been more urgent. FastWave's approach addresses this demand, providing cost-effective, minimally invasive solutions that substantially improve upon existing therapeutic options.
Accomplished interventional cardiologist, Dr. Sarang Mangalmurti, remarked, "Since its introduction, IVL technology has shown immense promise for treating complex calcium. I have high hopes that FastWave’s user-friendly systems will lead to improved clinical outcomes and a meaningful reduction in adverse events."
For more information: https://fastwavemedical.com
April 25, 2024 
